Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 205Breast Neoplasms 187Neoplasms 167Leukemia, Myeloid, Acute 164Multiple Myeloma 157Lymphoma 120Melanoma 117Neoplasm Metastasis 114Lymphoma, Non-Hodgkin 110Prostatic Neoplasms 109Leukemia 107Colorectal Neoplasms 96Recurrence 91Leukemia, Lymphocytic, Chronic, B-Cell 90Pancreatic Neoplasms 85Ovarian Neoplasms 85Myelodysplastic Syndromes 83Lung Neoplasms 83Lymphoma, Follicular 78Glioblastoma 78Precursor Cell Lymphoblastic Leukemia-Lymphoma 77Lymphoma, Large B-Cell, Diffuse 77Hodgkin Disease 69Lymphoma, Mantle-Cell 65Carcinoma, Renal Cell 62Brain Neoplasms 56Small Cell Lung Carcinoma 55Squamous Cell Carcinoma of Head and Neck 54Triple Negative Breast Neoplasms 52Sarcoma 52

Interventions

Radiation 1Paclitaxel 1Chemoradiotherapy 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Has results × Resectable Esophageal Cancer × Clear all
NCT03490292 2024-07-26

Avelumab With Chemoradiation for Stage II/III Resectable Esophageal and Gastroesophageal Cancer

University of Wisconsin, Madison

Phase 1/2 Completed
22 enrolled 17 charts
Gastrointestinal

Resectable Esophageal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡